A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Luke Mantle

Luke Mantle

Study ID

Protocol Number: 23-2225

More information available at ClinicalTrials.gov: NCT06112314

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers